VNDA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
69.8M
+38.2%
50.5M
-2.3%
51.7M
-9.6%
57.2M
+1.7%
56.3M
Cost of Revenue
4.2M
+16.6%
3.6M
+12.7%
3.2M
-17.6%
3.8M
+29.8%
3.0M
Gross Profit
65.7M
+39.8%
47.0M
-3.3%
48.6M
-9.0%
53.4M
+0.1%
53.3M
Operating Expenses
89.2M
-19.5%
110.8M
+12.1%
98.8M
+5.4%
93.7M
+10.8%
84.6M
R&D
27.6M
-25.3%
37.0M
+30.0%
28.4M
-2.0%
29.0M
+28.6%
22.6M
SG&A
59.6M
-17.1%
71.8M
+5.1%
68.4M
+8.5%
63.0M
+4.5%
60.3M
Operating Income
-23521000
+63.1%
-63809000
-27.0%
-50224000
-24.5%
-40353000
-29.0%
-31284000
EBITDA
-21291000
+65.4%
-61555000
-28.3%
-47964000
-25.2%
-38297000
-31.0%
-29231000
Net Income
-22562000
+63.9%
-62513000
-28.7%
-48567000
+65.6%
-141187000
-525.1%
-22586000
EPS (Basic)
$-0.37
+64.4%
$-1.04
-26.8%
$-0.82
+65.7%
$-2.39
-528.9%
$-0.38
EPS (Diluted)
$-0.37
+64.4%
$-1.04
-26.8%
$-0.82
+65.7%
$-2.39
-528.9%
$-0.38
Shares (Diluted)
60.5M
+0.4%
60.2M
+1.3%
59.5M
+0.6%
59.1M
+0.0%
59.1M
Vanda Pharmaceuticals (VNDA) — Financials